Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

• Status: Recruiting
• Trial end date: 2025-12-23
• Target enrollment: 0
• Participant gender: All

Summary

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: Adagrasib; Pembrolizumab

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of unresectable or metastatic NSCLC (squamous or nonsquamous) with KRAS G12C mutation and PD-L1 TPS ≥ 1%

Exclusion Criteria:

• Prior systemic treatment for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy (CIT), or any therapy targeting KRAS G12C mutation (eg, sotorasib)

• Radiation to the lung ≥ 30 Gy within 6 months prior to first dose of study treatment

• Active brain metastases